SavedAdd your journal

Journals / Astım Allerji İmmünoloji / 2021 / Cilt: 19 - Sayı: 2

Omalizumab Treatment in Chronic Spontaneous Urticaria During Pregnancy: Report of A Case and Review of the Literature

Andaç SALMAN
Meryem AKTAŞ
Pages
114–117
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, the safe and successful use of omalizumab updosing in a pregnant woman with CSU along with a review of the published literature is presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Omalizumab is a safe and effective treatment option for chronic spontaneous urticaria (CSU).
📊
Key Findings & Data:Although cohort studies in patients with asthma show no increased risk of congenital abnormalities, very little data exist in the literature regarding the use of omalizumab for CSU during pregnancy.
💡
Conclusion & Impact:Herein, the safe and successful use of omalizumab updosing in a pregnant woman with CSU along with a review of the published literature is presented.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Omalizumab is a safe and effective treatment option for chronic spontaneous urticaria (CSU). Although cohort studies in patients with asthma show no increased risk of congenital abnormalities, very little data exist in the literature regarding the use of omalizumab for CSU during pregnancy. Herein, the safe and successful use of omalizumab updosing in a pregnant woman with CSU along with a review of the published literature is presented.

🔖

Cite This Article

SALMAN, A., AKTAŞ, M. (2021). Omalizumab Treatment in Chronic Spontaneous Urticaria During Pregnancy: Report of A Case and Review of the Literature. Astım Allerji İmmünoloji, Cilt: 19 - Sayı: 2, 114–117. https://ajindex.com/articles/351205

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016;137:1742-50.e4
  2. Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (Spontaneous) urticaria: A meta-analysis of “real-world” evidence. JAMA Dermatol 2018;02467:1-30
  3. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393-414
  4. Maurer M, Abuzakouk M, Bérard F, Canonica W, Elberink HO, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy 2017;72:2005-16
  5. Kocatürk E, Al‐Ahmad M, Krause K et al. Changes in disease activity and treatment patterns in patients with chronic urticaria during pregnancy: Results of the PREG‐CU study, a UCARE project. Abstract. Allergy 2020; 75: 5-99
  6. Curto-Barredo L, Archilla LR, Vives GR, Pujol RM, Giménez-Arnau AM. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol 2018;98:641-7
  7. Namazy JA, Blais L, Andrews EB, ScheuerleAE, Cabana MD, Thorp JM, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol 2020;145:528-36.e1
  8. Vieira Dos Santos R, Locks Bidese B, Rabello de Souza J, Maurer M. Effects of omalizumab in a patient with three types of chronic urticaria. Br J Dermatol 2014;170:469-71
  9. Ghazanfar M, Thomsen S. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies. Case Rep Med 2015;2015:368053 10. Cuervo-Pardo L, Barcena-Blanch M, Radojicic C. Omalizumab use during pregnancy for CIU: A tertiary care experience. Eur Ann Allergy Clin Immunol 2016;48:145-6
  10. González-Medina M, Curto-Barredo L, Labrador-Horrillo M, Giménez-Arnau A. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): Report of two cases. J Eur Acad Dermatol Venereol 2017;31:e245-6
  11. Ensina L, Cusato-Ensina A, Camelo-Nunes I, Solé D. Omalizumab as third-line therapy for urticaria during pregnancy. J Investig Allergol Clin Immunol 2017;27:326-7. 1